Marché mondial des thérapies antituberculeuses – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché

Ces dernières années, le marché des thérapies antituberculeuses devrait connaître une croissance rapide au cours de la période de prévision. Selon le rapport mondial sur la tuberculose (TB) 2020 de l'OMS, environ 1,5 million de personnes sont mortes de la tuberculose (TB). La tuberculose est l'une des dix principales causes de décès dans le monde et la principale cause de décès causé par un seul agent infectieux. Dans l'ensemble, l'incidence mondiale de la tuberculose et de la tuberculose multirésistante constitue un défi pour les principaux organismes de réglementation médicale. L'implication significative de la communauté médicale et du gouvernement dans la lutte contre la tuberculose devrait entraîner une augmentation du nombre de diagnostics de tuberculose. Ainsi, cela a conduit à une forte demande pour le marché des thérapies antituberculeuses.

Français Data Bridge Market Research analyse que le marché des thérapies antituberculeuses était évalué à 1 266,27 millions USD en 2021 et devrait atteindre 2 127,36 millions USD d'ici 2029, enregistrant un TCAC de 6,70 % au cours de la période de prévision de 2022 à 2029. Le rapport de marché organisé par l'équipe de recherche sur le marché Data Bridge comprend une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Définition du marché

La tuberculose (TB) est une infection contagieuse qui affecte généralement les poumons. Cette maladie peut également se propager à d’autres parties du corps comme la colonne vertébrale et le cerveau. Mycobacterium tuberculosis est une forme de bactérie qui en est la cause. Les sociétés pharmaceutiques concentrent leurs efforts sur la création de médicaments qui peuvent réduire la durée du traitement et aider à surmonter les obstacles liés à la tuberculose sensible et résistante aux médicaments. Il existe deux formes de traitement de la tuberculose : le traitement de première intention, le traitement de deuxième intention et le traitement résistant aux médicaments.

Portée du rapport et segmentation du marché

Dynamique du marché des thérapies antituberculeuses

Conducteurs

• Augmentation de la prévalence de la tuberculose

La prévalence croissante de la tuberculose est un facteur majeur de la croissance du marché des thérapies antituberculeuses. Selon les données de l'OMS, en 2020, environ 10 millions de personnes ont contracté la tuberculose dans le monde. 3,3 millions étaient des femmes, 5,6 millions étaient des hommes et 1,1 million étaient des enfants. La transmission de la tuberculose (TB) se fait d'une personne à une autre par voie aérienne. Les personnes atteintes de tuberculose pulmonaire propagent les germes de la tuberculose dans l'air lorsqu'elles toussent, éternuent ou crachent. Une personne est infectée en inhalant quelques-uns de ces germes.

• Augmenter les investissements dans les infrastructures de santé

Un autre facteur important qui influence le taux de croissance du marché des thérapies antituberculeuses est l’augmentation des dépenses de santé, qui contribue à améliorer son infrastructure. En outre, diverses organisations gouvernementales visent à améliorer l’infrastructure des soins de santé en augmentant le financement, ce qui influencera davantage la dynamique du marché.

• Nombre croissant de personnes âgées

The rising geriatric population is expected to enhance the growth rate of anti-tuberculosis therapeutics market. Geriatric people are more prone to chronic and acute diseases due to the weak immune system. Various conditions such as diabetes, HIVAIDS, kidney diseases and others are the major factors that will weak the immune system. Along with this, certain medication, including chemotherapy, drugs used to treat Crohn's disease, rheumatoid arthritis, and psoriasis, will increase the risk of tuberculosis as these can weaken the immune system.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the anti-tuberculosis therapeutics market. Additionally, changing lifestyle of people and rising incidences of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) cases in developing countries will result in the expansion of anti-tuberculosis therapeutics market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the anti-tuberculosis therapeutics market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate. The advent of new and more efficient diabetic treatment and monitoring products is estimated to boost the market's growth rate in the future. 

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of the anti-tuberculosis therapeutics market during the forecast period.

Restraints/Challenges

On the other hand, the high cost of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) drugs will obstruct the market's growth rate. Developing economies' lack of healthcare infrastructure and product recalls will challenge the anti-tuberculosis therapeutics market. Additionally, side effects linked with anti-tuberculosis drugs will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This anti-tuberculosis therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the anti-tuberculosis therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Anti-tuberculosis therapeutics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Anti-Tuberculosis Therapeutics Market

Over the projected period, the anti-tuberculosis therapeutics market is expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations have imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world are having difficulty continuing their supply chain activities. The supply chain slowness has also hampered the anti-tuberculosis therapeutics market.

Global Anti-Tuberculosis Therapeutics Market Scope

The anti-tuberculosis therapeutics market is segmented on the basis of diseases type, treatment type, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Type

• Active TB
• Latent TB
• Others

Treatment Type

• First-Line of Drugs
  • Isoniazid
  • Ethambutol
  • Rifampin
  • Others
• Second-Line of Drugs
  • Thiacetazone
  • Paraaminosalicyclic Acid (PAS)
  • Others
• Others

Diagnosis

• Blood Tests
• Imaging Tests
  • Chest X-ray
  • CT scan
• Sputum Tests
• Others

Dosage form

• Tablets
• Capsules
• Injections
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Anti-Tuberculosis Therapeutics Market Regional Analysis/Insights

The anti-tuberculosis therapeutics market is analysed and market size insights and trends are provided by country, diseases type, treatment type, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Anti-tuberculosis therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the anti-tuberculosis therapeutics market because of the growing number of research and development activities and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, increasing adoption of Bacillus Calmette–Guérin (BCG) vaccine will further influence the market's growth rate in this region

Asia-Pacific are expected to grow during the forecast period due to surging number of generic manufacturers in this region. Also, development of healthcare infrastructure and increasing government initiatives will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Anti-Tuberculosis Therapeutics Market Share Analysis

The Anti-tuberculosis therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to anti-tuberculosis therapeutics market.

Some of the major players operating in the anti-tuberculosis therapeutics market are:

• AstraZeneca (UK)
• Johnson & Johnson Private Limited (US)
• Eli Lilly and Company (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Novartis AG (Switzerland)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Allergan (Ireland)
• Merck & Co., Inc. (US)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (Royaume-Uni) 
• Hikma Pharmaceuticals PLC (Royaume-Uni)
• Cipla Inc. (États-Unis)
• Lannett (États-Unis)
• Fresenius Kabi AG (Allemagne)
• Endo International plc (Irlande)
• Otsuka Pharmaceutical Co., Ltd. (Japon)
• STI Pharma, LLC (États-Unis)
• Macleods Pharmaceuticals Ltd. (Inde)

SKU-53710